SYMTUZA® (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide), PREZCOBIX® (darunavir/cobicistat), PREZISTA® (darunavir), INTELENCE® (etravirine), and EDURANT® (rilpivirine) -

Media Statement - April 2022 - Johnson & Johnson Takes Further Legal Action to Help End the Distribution of Counterfeit HIV Medicines in the United States

## SUMMARY

- On April 26, 2022, the Johnson & Johnson pharmaceutical company issued a media statement confirming that they have taken further legal action to help end the distribution of counterfeit medicines for the treatment of human immunodeficiency virus (HIV) in the United States following an investigation that identified criminal activity involving distributors not authorized to sell Johnson & Johnson medicines.
- Please click here for the link to the Media Statement.<sup>1</sup>

## REFERENCE

1. Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen Takes Further Legal Action to Help End the Distribution of Counterfeit HIV Medicines in the United States. 26 April 2022. Available at: <a href="https://www.janssen.com/us/sites/www\_janssen\_com\_usa/files/janssen\_takes\_further\_legal\_action\_to\_help\_end\_the\_distribution\_of\_counterfeit\_hiv\_medicines\_in\_the\_united\_states.pdf">https://www.janssen.com/us/sites/www\_janssen\_com\_usa/files/janssen\_takes\_further\_legal\_action\_to\_help\_end\_the\_distribution\_of\_counterfeit\_hiv\_medicines\_in\_the\_united\_states.pdf</a>.